<SEC-DOCUMENT>0001193125-18-242792.txt : 20180808
<SEC-HEADER>0001193125-18-242792.hdr.sgml : 20180808
<ACCEPTANCE-DATETIME>20180808162558
ACCESSION NUMBER:		0001193125-18-242792
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180808
DATE AS OF CHANGE:		20180808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		181001734

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d597946d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;8, 2018 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-30171</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>68-0359556</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>501 Canal Blvd., Richmond, California 94804 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) 970-6000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth
company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Results of Operations and Financial Condition. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;8, 2018, Sangamo Therapeutics, Inc. (&#147;Sangamo&#148;) issued a press release announcing its financial results for the
quarter ended June&nbsp;30, 2018 (the &#147;Press Release&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is
incorporated by reference herein. The information contained in this Item&nbsp;2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item&nbsp;2.02 and in the Press Release
furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the SEC made by Sangamo whether made before or after the date hereof, regardless of any general incorporation language in such
filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)<I> Exhibits</I>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d597946dex991.htm">Press Release dated August 8, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">SANGAMO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;8, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heather Turner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d597946dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g597946sangamologo.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Sangamo Therapeutics, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Point Richmond Tech Center</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">501 Canal
Boulevard</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Richmond, CA 94804</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">510-970-6000 | sangamo.com</P></TD></TR>
</TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Also Separately Announced Positive Preliminary Data from Phase 1/2 Clinical Trial </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Evaluating SB-525 Gene Therapy for Hemophilia A </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Today </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Richmond, California</B>, <B>August&nbsp;8, 2018 </B>&#150; Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported second quarter 2018 financial results
and recent accomplishments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In the first half of 2018 we made strong progress on important initiatives including our clinical development programs
and execution of a significant collaboration with Kite-Gilead for the use of ZFNs for engineered cell therapies in oncology,&#148; said Sandy Macrae, CEO of Sangamo. &#147;More recently, with our proposed acquisition of TxCell, we have the
opportunity to seize a leadership position in the development of gene-edited cell therapies for immunological diseases, one of our therapeutic areas of focus for our proprietary pipeline.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Macrae continued: &#147;Today we announced positive preliminary data from the Alta clinical trial evaluating SB-525 gene therapy for hemophilia A. These are
the first efficacy data from our clinical programs using AAV6. We are looking forward to the September&nbsp;5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> SSIEM presentation of preliminary data from the CHAMPIONS Study evaluating SB-913,
our <I>in vivo</I> genome editing candidate for MPS II.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Highlights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Announced the proposed acquisition of TxCell, positioning Sangamo as a leader in CAR-Treg development
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Appointed Karen Smith, M.D., Ph.D., to the Board of Directors, and Edward Rebar, Ph.D., as Senior Vice President
and Chief Technology Officer </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Today announced positive preliminary data from the Phase 1/2 Alta Study evaluating SB-525 gene therapy for
hemophilia&nbsp;A </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treated the fifth and sixth patients in the SB-913 Phase 1/2 CHAMPIONS Study for MPS II </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treated the first patient in the SB-318 Phase 1/2 EMPOWERS Study for MPS I </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Received Clinical Trial Authorisation (CTA) in the U.K. for enrollment of subjects into ongoing Phase 1/2
clinical trials evaluating SB-318 and SB-913 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enrolled the first patient in the Phase 1/2 Thales Study evaluating ST-400 gene-edited cell therapy for the
treatment of beta-thalassemia </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Delivered three oral and four poster presentations during the
21<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Annual Meeting of the American Society of Gene&nbsp;&amp; Cell Therapy (ASGCT) held in Chicago, IL from May&nbsp;16-19, 2018 </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Second Quarter Ended June&nbsp;30, 2018 Financial Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the second quarter ended June&nbsp;30, 2018, Sangamo reported a consolidated net loss of $16.6 million, or $0.17 per share, compared to a net loss of $12.5
million, or $0.17 per share, for the same period in 2017. As of June&nbsp;30, 2018, the Company had cash, cash equivalents, marketable securities and interest receivable of $574.2 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues for the second quarter ended June&nbsp;30, 2018 were $21.4 million, compared to $8.3 million for the same period in 2017. The increase in revenues
was primarily related to the collaborations and licensing agreements with Pfizer, for hemophilia A, and Kite, a Gilead company, for gene-edited cell therapies for oncology. Second quarter 2018 revenues were primarily generated from Sangamo&#146;s
collaboration agreements with Kite, Pfizer and Bioverativ, a Sanofi company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total operating expenses for the second quarter ended June&nbsp;30, 2018
were $40.6 million, compared to $21.0 million for the same period in 2017. Research and development expenses were $29.3 million for the second quarter ended June&nbsp;30, 2018, compared to $15.0 million for the same period in 2017. The increase was
primarily due to clinical and manufacturing expenses in support of current clinical studies and investment in dedicated manufacturing capacity. General and administrative expenses were $11.3 million for the second quarter ended June&nbsp;30, 2018,
compared to $6.0 million for the same period in 2017. The increase was primarily due to salaries and related costs and other professional fees in support of overall Company growth. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Guidance for 2018 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo will provide updated
guidance on expected operating expenses in future quarterly reporting periods. The Company updates cash guidance as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash and Investments:</B> Sangamo expects a December&nbsp;31, 2018 balance of cash, cash equivalents,
marketable securities and interest receivable of at least $380 million. This anticipated cash balance is inclusive of research funding from existing collaborators and recent financings. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo will host a conference call
today, August&nbsp;8, 2018, at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under <U>Events and
Presentations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conference call dial-in numbers are (877)&nbsp;377-7553 for domestic callers and (678)&nbsp;894-3968 for international callers.
The conference ID number for the call is 7179826. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on August&nbsp;8, 2018 to
11:59 p.m. ET on August&nbsp;15, 2018. The conference call replay numbers for domestic and international callers are (855)&nbsp;859-2056 and (404)&nbsp;537-3406, respectively. The conference ID number for the replay is 7179826. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Sangamo </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo Therapeutics is focused on
translating ground-breaking science into genomic therapies that transform patients&#146; lives using the Company&#146;s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo,
visit <U>www.sangamo.com</U>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements regarding Sangamo&#146;s current expectations. These forward-looking statements include, without
limitation, the expectation of the acquisition by Sangamo of TxCell, the anticipated timing and benefits thereof; Sangamo&#146;s belief of the potential of CAR-Treg therapies to treat immunological diseases; the planned September&nbsp;5th SSIEM
presentation of preliminary data from the CHAMPIONS Study evaluating SB-913, our in vivo genome editing candidate for MPS II, and the year-end financial guidance provided related to cash, cash equivalents, marketable securities and interest
receivable. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to,
the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation and completion of clinical trials, including the Alta study, the fact that the
preliminary observations from the Alta study are based on preliminary data from only the first five patients in the study and that these preliminary data may not be representative of final results after all patients are treated in the study and all
data are collected and analyzed; whether the final results from the Alta study will validate and support the safety and efficacy of SB-525, Sangamo&#146;s reliance on partners and other third-parties to meet their clinical and manufacturing
obligations, and the ability to maintain strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable product
candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo&#146;s operations and business environments. These risks and uncertainties are described more fully in
Sangamo&#146;s Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2018 as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes
no duty to update such information except as required under applicable law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Sangamo Therapeutics, Inc. </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McDavid Stilwell </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510) 970-6000, x219 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mstilwell@sangamo.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Varant Shirvanian </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510) 970-6000, x205 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>vshirvanian@sangamo.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-more- </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">(unaudited; in thousands, except per share data) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of
Operations Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three months ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SELECTED BALANCE SHEET DATA </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, marketable securities and interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">574,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">244,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">627,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g597946sangamologo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g597946sangamologo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !P 30# 2(  A$! Q$!_\0
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ME>9_$'_@Y%_:.\8:\;C0K7P#X2L5^[9PZ8^H$C_;DE;.?7: *^+?@G\'=?\
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M5K@7&H>'-1D:.%I. TL$B\PRE1@G!4X&5.*^LPO"\L3@%BL/-2F^FR\U?O\
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M^#JQIXFG4J?#&2;]$TS^BN/JV:9CDE;#T<'*+M>3DXM*W\MFW+ULK*Y\8_\
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MGP<)\\(6=FNO73\C\IO^"7__  0@^)O[''[8&B_$KQQXT\!7>G>';6Y2WLM
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M9XR)K1<\[/WL8S\J(.OZ$Z=\0]!_9U^$'A5?'.NZ7X=-OIUKI[S7URL:-<)
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MY1+ /M/.TE6Y]C7JU.*LRG:TTK:Z):^OEY'GT>%\)=QC3<F_5GPA_P $T/\
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<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
